Dutch Bros to Post Q1 Earnings: What's in the Cards for the Stock?
BROS is set to report Q1 2026 on May 6, with EPS and revenues seen rising on same-shop gains and new…
zacks.com
NBIX(NBIX)
NBIX
Earnings in 1 day · May 5, 2026 · After close
Signal
Leaning Bullish1↑
PRICE
Prev Close
131.78
Open
131.78
Day Range131.78 – 133.81
131.78
133.81
52W Range108.35 – 160.18
108.35
160.18
48% of range
VOLUME & SIZE
Avg Volume
1.2M
FUNDAMENTALS
P/E Ratio
28.4x
EPS (TTM)
—
Div Yield
No dividend
Beta
0.52
Low vol
Quick Read
Trend—Insufficient MA data
Momentum
BULLISH
revenue +21% YoY · 98% gross marginValuation
EXPENSIVE
P/E 28x vs ~20x sectorHealth
STRONG
CR 3.4 · FCF $7.52/shBullish
Key MetricsTTM
Market Cap$13.35B
Revenue TTM$2.86B
Net Income TTM$478.60M
Free Cash Flow$748.70M
Gross Margin98.2%
Net Margin16.7%
Operating Margin21.6%
Return on Equity16.7%
Return on Assets10.3%
Debt / Equity0.13
Current Ratio3.39
EPS TTM$4.81
Alpha SignalsView Intelligence →
Intelligence analysis not yet available for this stock. Full AI-powered analysis may be available on the intelligence page.
Health Radar
3 strong2 watch1 concern
57/100Liquidity
3.39Strong
Leverage
0.13Strong
Coverage
0.0xConcern
ROE
16.7%Strong
ROIC
10.8%Watch
Cash
$713MWatch
ANALYST COVERAGE28 analysts
BUY
▲ +33.8%upside to target
L $140.00
Med $178.00consensus
H $220.00Stock Health
Composite Score
4 of 4 signals bullish
10/10
Technicals
●
✓RSI RangeRSI 51 — Bullish momentum
Fundamentals
●
✓Last EarningsBeat estimates
●
✓Analyst ConsensusBuy
●
✓LiquidityCurrent Ratio 3.39 — healthy liquidity
1 signal unavailable — limited data for this stock
Upcoming Events
EEarnings ReportMay 5, 2026
Tomorrow
DEx-Dividend DateAug 2, 2026
In 90 days
FinancialsFull statements →
Technicals
Technical SetupBEARISH
Technicals →Trend
→ PullbackGolden Cross · 50D leads 200D by 19.2%
-8.8% vs SMA 50 · +8.7% vs SMA 200
Momentum
RSI50.9Neutral territory
MACD-2.78Below zero — bearish pulse · compressing
Market Position
Price Levels
52W High
$160.2+20.4%
EMA 50
$145.0+9.0%
Current
$133.0
EMA 200
$122.4-8.0%
52W Low
$108.3-18.6%
52-Week RangeMid-range
$108.348th %ile$160.2
Earnings & Analysts
ANALYST ESTIMATES
Consensus of 20 analysts
Analyst revisions:EPS↓ Revised DownRevenue↓ Revised Down
Analyst consensus estimates · Actuals replace estimates as reported
| Year | Revenue Est. | Rev Gth | EPS Est. | EPS Gth | Range | Analysts |
|---|---|---|---|---|---|---|
FY2025 | $2.8B $2.8B–$2.9B | — | $5.04 | — | ±5% | High20 |
FY2026(current) | $3.5B $3.4B–$3.5B | ▲ +22.3% | $6.11 | ▲ +21.2% | ±13% | High13 |
FY2027 | $3.9B $3.7B–$4.1B | ▲ +11.1% | $8.38 | ▲ +37.3% | ±22% | High10 |
Range confidence:Tight (high)ModerateWide (low)
Earnings HistoryNBIX
Last 8Q
-24.7%avg beat
Beat 3 of 8 quartersMissed 5↓ Estimates falling-58%
Q2'24
-40%
Q3'24
-18%
Q4'24
-38%
Q1'25
-85%
Q2'25
+8%
Q3'25
+29%
Q4'25
+4%
Q1'26
Beat
Miss
Estimate
Deeper color = bigger beat/miss
Analyst Activity
All ratings →No recent activity
Piper SandlerOverweight
Aug 29
UPGRADE
Wells FargoBuy → Overweight
Apr 23
UPGRADE
MoffettNathansonOutperform
Jul 24
UPGRADE
Leerink PartnersOutperform
Jul 24
UPGRADE
BMO CapitalMarket Perform → Perform
Jul 6
UPGRADE
BMO CapitalMarket Perform
Jul 6
UPGRADE
GuggenheimBuy
May 4
UPGRADE
Canaccord GenuityBuy
Mar 30
UPGRADE
Evercore ISIOutperform
Mar 3
UPGRADE
Morgan StanleyOverweight
Feb 3
UPGRADE
Financials
INSTITUTIONAL OWNERSHIP
1
Pictet Asset Management Holding SA
603K▼2
Swedbank AB
579K▼3
Nuveen, LLC
443K▲4
Candriam S.C.A.
275K▼5
Sumitomo Mitsui Trust Holdings, Inc.
220K▲6
Handelsbanken Fonder AB
188K▼7
HSBC HOLDINGS PLC
184K▲8
Retirement Systems of Alabama
123K▲News & Activity
NBIX News
20 articles · 4h ago
Why Zions (ZION) is a Great Dividend Stock Right Now
zacks.com
Gen Digital to Report Q4 Earnings: What's in Store for the Stock?
zacks.com
COPT Defense (CDP) Could Be a Great Choice
zacks.com
Why Trustmark (TRMK) is a Top Dividend Stock for Your Portfolio
zacks.com
Why Associated Banc-Corp (ASB) is a Great Dividend Stock Right Now
zacks.com
Why First Commonwealth Financial (FCF) is a Top Dividend Stock for Your Portfolio
zacks.com
Why HSBC (HSBC) is a Top Dividend Stock for Your Portfolio
zacks.com
Canadian Imperial Bank (CM) Could Be a Great Choice
zacks.com
American International Group (AIG) Could Be a Great Choice
zacks.com
Why MarketAxess (MKTX) is a Great Dividend Stock Right Now
zacks.com
Why Banco Santander-Chile (BSAC) is a Great Dividend Stock Right Now
zacks.com
Why Independent Bank Corp. (INDB) is a Top Dividend Stock for Your Portfolio
zacks.com
Are You Looking for a High-Growth Dividend Stock?
zacks.com
Why United Bankshares (UBSI) is a Top Dividend Stock for Your Portfolio
zacks.com
COTY INVESTOR NOTICE: Faruqi & Faruqi, LLP Reminds Coty (COTY) Investors of Securities Class Action Deadline on May 22, 2026
newsfilecorp.com
Why are UPS, FedEx stocks falling today?
invezz.com
Hess Midstream LP (HESM) Q1 2026 Earnings Call Transcript
seekingalpha.com
Anthropic teams with Goldman, Blackstone and others on $1.5 billion AI venture targeting PE-owned firms
cnbc.com
YOOV INVESTOR NOTICE: Faruqi & Faruqi, LLP Reminds Concorde International (YOOV) Investors of Securities Class Action Deadline on May 20, 2026
newsfilecorp.com
About
neurocrine biosciences, inc of san diego is a product based biopharmaceutical company focusing on the development and commercialization of innovative pharmaceutical products to treat unmet medical needs. the company's research and development efforts are focused on neurological and endocrine diseases and disorders. our product candidates address some of the largest pharmaceutical markets in the world including endometriosis, irritable bowel syndrome, anxiety, depression, pain, diabetes, insomnia, and other neurological and endocrine related diseases and disorders
Industry
Research and Development in Biotechnology (except Nanobiotechnology)
CEO
Kevin Gorman
Website
Kyle W. GanoPresident, CEO & Director
Todd TushlaVice President of Investor Relations